{"transactions":[{"id":2264704,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Ordinary Shares","published_at":"2022-05-19T11:31:18.000Z","date":"2022-05-17","kind":"sale","acquired":false,"shares":130000,"price":8.2159,"value":1068067.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.185 to\n$8.240, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer,\nfull information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The shares held by the reporting person prior to the sale reported in this Form 4 included 5,300 Ordinary Shares previously issued to the reporting person in exempt transactions in connection with the settlement of certain equity-based awards granted to the reporting person, which were inadvertently omitted from the reporting person's previously reported amount of securities beneficially owned."}],"balance_after":1386.514,"source":{"system":"sec-edgar","filing":"0001209191-22-030308","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919122030308/doc4.xml","form_type":"4"}},{"id":2345921,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Restricted Share Units","published_at":"2022-03-08T21:07:49.000Z","date":"2022-03-05","kind":"exercise","acquired":false,"shares":23764,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources\nand Compensation Committee, the cash value of one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"Restricted share units were granted on March 5, 2021, with 23,764 having vested on March 5, 2022, 23,764 vesting on each of March 5, 2023 and March 5, 2024, and 23,765 vesting on March 5, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F10","text":"Restricted share units were granted on March 5, 2021, with 23,764 having vested on March 5, 2022, 23,764 vesting on each of March 5, 2023 and March 5, 2024, and 23,765 vesting on March 5, 2025."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":71293,"derivative":{"underlying":"Ordinary Shares","underlying_shares":23764},"source":{"system":"sec-edgar","filing":"0001209191-22-017046","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919122017046/doc4.xml","form_type":"4"}},{"id":2345920,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Restricted Share Units","published_at":"2022-03-08T21:07:49.000Z","date":"2022-03-04","kind":"grant","acquired":true,"shares":140750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources\nand Compensation Committee, the cash value of one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"Restricted share units were granted on March 4, 2022, with 35,187 vesting on each of March 4, 2023, March 4, 2024 and March 4, 2025, and 35,189\nvesting on March 4, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"Restricted share units were granted on March 4, 2022, with 35,187 vesting on each of March 4, 2023, March 4, 2024 and March 4, 2025, and 35,189\nvesting on March 4, 2026."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":140750,"derivative":{"underlying":"Ordinary Shares","underlying_shares":140750},"source":{"system":"sec-edgar","filing":"0001209191-22-017046","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919122017046/doc4.xml","form_type":"4"}},{"id":2345919,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Restricted Share Units","published_at":"2022-03-08T21:07:49.000Z","date":"2022-03-04","kind":"exercise","acquired":false,"shares":18905,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources\nand Compensation Committee, the cash value of one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"Restricted share units were granted on March 4, 2019, with 18,905 having vested on each of March 4, 2021 and March 4, 2022, and 18,906 vesting on March 4, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"Restricted share units were granted on March 4, 2019, with 18,905 having vested on each of March 4, 2021 and March 4, 2022, and 18,906 vesting on March 4, 2023."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":18906,"derivative":{"underlying":"Ordinary Shares","underlying_shares":18905},"source":{"system":"sec-edgar","filing":"0001209191-22-017046","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919122017046/doc4.xml","form_type":"4"}},{"id":2345918,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Restricted Share Units","published_at":"2022-03-08T21:07:49.000Z","date":"2022-03-04","kind":"exercise","acquired":false,"shares":51488,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources\nand Compensation Committee, the cash value of one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Restricted share units were received on February 8, 2022 upon satisfaction of performance criteria and vested on March 4, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Restricted share units were received on February 8, 2022 upon satisfaction of performance criteria and vested on March 4, 2022."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":51488},"source":{"system":"sec-edgar","filing":"0001209191-22-017046","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919122017046/doc4.xml","form_type":"4"}},{"id":2345917,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Ordinary Shares","published_at":"2022-03-08T21:07:49.000Z","date":"2022-03-07","kind":"sale","acquired":false,"shares":8941,"price":7.3667,"value":65865.6647,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"kind","element":"transactionCoding","label":"F3","text":"The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F4","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting\nof the restricted share units listed in Table II."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.30 to $7.49, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":126086.514,"source":{"system":"sec-edgar","filing":"0001209191-22-017046","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919122017046/doc4.xml","form_type":"4"}},{"id":2345916,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Ordinary Shares","published_at":"2022-03-08T21:07:49.000Z","date":"2022-03-05","kind":"exercise","acquired":true,"shares":23764,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources\nand Compensation Committee, the cash value of one ordinary share."}],"balance_after":135027.514,"source":{"system":"sec-edgar","filing":"0001209191-22-017046","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919122017046/doc4.xml","form_type":"4"}},{"id":2345915,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Ordinary Shares","published_at":"2022-03-08T21:07:49.000Z","date":"2022-03-04","kind":"sale","acquired":false,"shares":6618,"price":7.4825,"value":49519.185,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"kind","element":"transactionCoding","label":"F3","text":"The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F4","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting\nof the restricted share units listed in Table II."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.40 to $7.60, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":111263.514,"source":{"system":"sec-edgar","filing":"0001209191-22-017046","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919122017046/doc4.xml","form_type":"4"}},{"id":2345914,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Ordinary Shares","published_at":"2022-03-08T21:07:49.000Z","date":"2022-03-04","kind":"exercise","acquired":true,"shares":18905,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources\nand Compensation Committee, the cash value of one ordinary share."}],"balance_after":117881.514,"source":{"system":"sec-edgar","filing":"0001209191-22-017046","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919122017046/doc4.xml","form_type":"4"}},{"id":2345913,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Ordinary Shares","published_at":"2022-03-08T21:07:49.000Z","date":"2022-03-04","kind":"sale","acquired":false,"shares":18020,"price":7.4825,"value":134834.65,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"kind","element":"transactionCoding","label":"F3","text":"The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F4","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting\nof the restricted share units listed in Table II."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.40 to $7.60, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":98976.514,"source":{"system":"sec-edgar","filing":"0001209191-22-017046","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919122017046/doc4.xml","form_type":"4"}},{"id":2345912,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Ordinary Shares","published_at":"2022-03-08T21:07:49.000Z","date":"2022-03-04","kind":"exercise","acquired":true,"shares":51488,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources\nand Compensation Committee, the cash value of one ordinary share."}],"balance_after":116996.514,"source":{"system":"sec-edgar","filing":"0001209191-22-017046","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919122017046/doc4.xml","form_type":"4"}},{"id":2363034,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Restricted Share Units","published_at":"2022-03-02T12:47:04.000Z","date":"2022-02-28","kind":"exercise","acquired":false,"shares":21682,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources\nand Compensation Committee, the cash value of one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Restricted share units were granted on February 28, 2020, with 21,682 having vested on each of February 28, 2021 and February 28, 2022, 21,682 vesting on February 28, 2023 and 21,684 vesting on February 28, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Restricted share units were granted on February 28, 2020, with 21,682 having vested on each of February 28, 2021 and February 28, 2022, 21,682 vesting on February 28, 2023 and 21,684 vesting on February 28, 2024."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":43366,"derivative":{"underlying":"Ordinary Shares","underlying_shares":21682},"source":{"system":"sec-edgar","filing":"0001209191-22-014469","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919122014469/doc4.xml","form_type":"4"}},{"id":2363033,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Ordinary Shares","published_at":"2022-03-02T12:47:04.000Z","date":"2022-02-28","kind":"sale","acquired":false,"shares":7590,"price":8.1422,"value":61799.298,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"kind","element":"transactionCoding","label":"F3","text":"The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F4","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting\nof the restricted share units listed in Table II."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.035 to $8.255,\ninclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full\ninformation regarding the number of shares sold at each separate price."}],"balance_after":65508.514,"source":{"system":"sec-edgar","filing":"0001209191-22-014469","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919122014469/doc4.xml","form_type":"4"}},{"id":2363032,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Ordinary Shares","published_at":"2022-03-02T12:47:04.000Z","date":"2022-02-28","kind":"exercise","acquired":true,"shares":21682,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources\nand Compensation Committee, the cash value of one ordinary share."}],"balance_after":73098.514,"source":{"system":"sec-edgar","filing":"0001209191-22-014469","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919122014469/doc4.xml","form_type":"4"}},{"id":2405262,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Restricted Share Units","published_at":"2022-02-10T21:09:39.000Z","date":"2022-02-08","kind":"grant","acquired":true,"shares":51488,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources\nand Compensation Committee, the cash value of one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to\ntime-based vesting and will vest on March 4, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to\ntime-based vesting and will vest on March 4, 2022."}],"balance_after":51488,"derivative":{"underlying":"Ordinary Shares","underlying_shares":51488},"source":{"system":"sec-edgar","filing":"0001209191-22-008415","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919122008415/doc4.xml","form_type":"4"}},{"id":2405261,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Restricted Share Units","published_at":"2022-02-10T21:09:39.000Z","date":"2022-02-09","kind":"exercise","acquired":false,"shares":16121,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources\nand Compensation Committee, the cash value of one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Restricted share units were granted on February 9, 2018, with 16,120 having vested on each of February 9, 2020 and February 9, 2021 and 16,121\nhaving vested on February 9, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Restricted share units were granted on February 9, 2018, with 16,120 having vested on each of February 9, 2020 and February 9, 2021 and 16,121\nhaving vested on February 9, 2022."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":16121},"source":{"system":"sec-edgar","filing":"0001209191-22-008415","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919122008415/doc4.xml","form_type":"4"}},{"id":2405260,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Ordinary Shares","published_at":"2022-02-10T21:09:39.000Z","date":"2022-02-09","kind":"sale","acquired":false,"shares":6116,"price":9.0602,"value":55412.1832,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"kind","element":"transactionCoding","label":"F3","text":"The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F4","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting\nof the restricted share units listed in Table II."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.06 to $9.075,\ninclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full\ninformation regarding the number of shares sold at each separate price."}],"balance_after":51416.514,"source":{"system":"sec-edgar","filing":"0001209191-22-008415","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919122008415/doc4.xml","form_type":"4"}},{"id":2405259,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Ordinary Shares","published_at":"2022-02-10T21:09:39.000Z","date":"2022-02-09","kind":"exercise","acquired":true,"shares":16121,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources\nand Compensation Committee, the cash value of one ordinary share."}],"balance_after":57532.514,"source":{"system":"sec-edgar","filing":"0001209191-22-008415","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919122008415/doc4.xml","form_type":"4"}},{"id":2606062,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Ordinary Shares","published_at":"2021-08-12T20:04:06.000Z","date":"2021-08-10","kind":"sale","acquired":false,"shares":50860,"price":9.9493,"value":506021.398,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.91 to $10.00, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":41411.514,"source":{"system":"sec-edgar","filing":"0001209191-21-051075","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919121051075/doc4.xml","form_type":"4"}},{"id":2715437,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Restricted Share Units","published_at":"2021-05-13T11:45:38.000Z","date":"2021-05-11","kind":"exercise","acquired":false,"shares":37884,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Restricted share units were granted on February 9, 2021 pursuant to the satisfaction of performance criteria and vested on May 11, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Restricted share units were granted on February 9, 2021 pursuant to the satisfaction of performance criteria and vested on May 11, 2021."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":37884},"source":{"system":"sec-edgar","filing":"0001209191-21-032252","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919121032252/doc4.xml","form_type":"4"}},{"id":2715436,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Ordinary Shares","published_at":"2021-05-13T11:45:38.000Z","date":"2021-05-11","kind":"sale","acquired":false,"shares":19066,"price":10.2187,"value":194829.7342,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"kind","element":"transactionCoding","label":"F3","text":"The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F4","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.205 to $10.230, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":92271.514,"source":{"system":"sec-edgar","filing":"0001209191-21-032252","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919121032252/doc4.xml","form_type":"4"}},{"id":2715435,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Ordinary Shares","published_at":"2021-05-13T11:45:38.000Z","date":"2021-05-11","kind":"exercise","acquired":true,"shares":37884,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."}],"balance_after":111337.514,"source":{"system":"sec-edgar","filing":"0001209191-21-032252","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919121032252/doc4.xml","form_type":"4"}},{"id":2804322,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Restricted Share Units","published_at":"2021-03-08T21:07:20.000Z","date":"2021-03-05","kind":"grant","acquired":true,"shares":95057,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Restricted share units were granted on March 5, 2021, with 23,764 vesting on each of March 5, 2022, March 5, 2023, March 5, 2024 and 23,765 vesting on March 5, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Restricted share units were granted on March 5, 2021, with 23,764 vesting on each of March 5, 2022, March 5, 2023, March 5, 2024 and 23,765 vesting on March 5, 2025."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":95057,"derivative":{"underlying":"Ordinary Shares","underlying_shares":95057},"source":{"system":"sec-edgar","filing":"0001209191-21-018518","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919121018518/doc4.xml","form_type":"4"}},{"id":2804321,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Restricted Share Units","published_at":"2021-03-08T21:07:20.000Z","date":"2021-03-04","kind":"exercise","acquired":false,"shares":18905,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Restricted share units were granted on March 4, 2019, with 18,905 vesting on each of March 4, 2021 and March 4, 2022 and 18,906 vesting on March 4, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Restricted share units were granted on March 4, 2019, with 18,905 vesting on each of March 4, 2021 and March 4, 2022 and 18,906 vesting on March 4, 2023."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":37811,"derivative":{"underlying":"Ordinary Shares","underlying_shares":18905},"source":{"system":"sec-edgar","filing":"0001209191-21-018518","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919121018518/doc4.xml","form_type":"4"}},{"id":2804320,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Ordinary Shares","published_at":"2021-03-08T21:07:20.000Z","date":"2021-03-04","kind":"sale","acquired":false,"shares":9515,"price":10.5661,"value":100536.4415,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"kind","element":"transactionCoding","label":"F3","text":"The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F4","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.510 to $10.690, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":73453.514,"source":{"system":"sec-edgar","filing":"0001209191-21-018518","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919121018518/doc4.xml","form_type":"4"}},{"id":2804319,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Ordinary Shares","published_at":"2021-03-08T21:07:20.000Z","date":"2021-03-04","kind":"exercise","acquired":true,"shares":18905,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."}],"balance_after":82968.514,"source":{"system":"sec-edgar","filing":"0001209191-21-018518","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919121018518/doc4.xml","form_type":"4"}},{"id":2810200,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Ordinary Shares","published_at":"2021-03-04T21:03:17.000Z","date":"2021-03-02","kind":"sale","acquired":false,"shares":50000,"price":10.8178,"value":540890.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.790 to $10.870, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":64063.514,"source":{"system":"sec-edgar","filing":"0001209191-21-017758","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919121017758/doc4.xml","form_type":"4"}},{"id":2823330,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Restricted Share Units","published_at":"2021-03-02T21:05:46.000Z","date":"2021-02-28","kind":"exercise","acquired":false,"shares":21682,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Restricted share units were granted on February 28, 2020 with 21,682 vesting on each of February 28, 2021, February 28, 2022 and February 28, 2023 and 21,684 vesting on February 28, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Restricted share units were granted on February 28, 2020 with 21,682 vesting on each of February 28, 2021, February 28, 2022 and February 28, 2023 and 21,684 vesting on February 28, 2024."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":65048,"derivative":{"underlying":"Ordinary Shares","underlying_shares":21682},"source":{"system":"sec-edgar","filing":"0001209191-21-015842","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919121015842/doc4.xml","form_type":"4"}},{"id":2823329,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Ordinary Shares","published_at":"2021-03-02T21:05:46.000Z","date":"2021-03-01","kind":"sale","acquired":false,"shares":10912,"price":10.8308,"value":118185.6896,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"kind","element":"transactionCoding","label":"F3","text":"The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F4","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.78 to $11.01, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":114063.514,"source":{"system":"sec-edgar","filing":"0001209191-21-015842","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919121015842/doc4.xml","form_type":"4"}},{"id":2823328,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Ordinary Shares","published_at":"2021-03-02T21:05:46.000Z","date":"2021-02-28","kind":"exercise","acquired":true,"shares":21682,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."}],"balance_after":124975.514,"source":{"system":"sec-edgar","filing":"0001209191-21-015842","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919121015842/doc4.xml","form_type":"4"}},{"id":2856613,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Restricted Share Units","published_at":"2021-02-17T21:07:11.000Z","date":"2021-02-14","kind":"exercise","acquired":false,"shares":5355,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Restricted share units were granted on February 14, 2017, with 5,353 vesting on each of February 14, 2019 and February 14, 2020 and 5,355 vesting on February 14, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Restricted share units were granted on February 14, 2017, with 5,353 vesting on each of February 14, 2019 and February 14, 2020 and 5,355 vesting on February 14, 2021."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":5355},"source":{"system":"sec-edgar","filing":"0001209191-21-011244","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919121011244/doc4.xml","form_type":"4"}},{"id":2856612,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Ordinary Shares","published_at":"2021-02-17T21:07:11.000Z","date":"2021-02-16","kind":"sale","acquired":false,"shares":2098,"price":11.1229,"value":23335.8442,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"kind","element":"transactionCoding","label":"F3","text":"The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F4","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.105 to $11.135, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":103293.514,"source":{"system":"sec-edgar","filing":"0001209191-21-011244","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919121011244/doc4.xml","form_type":"4"}},{"id":2856611,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Ordinary Shares","published_at":"2021-02-17T21:07:11.000Z","date":"2021-02-14","kind":"exercise","acquired":true,"shares":5355,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."}],"balance_after":105391.514,"source":{"system":"sec-edgar","filing":"0001209191-21-011244","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919121011244/doc4.xml","form_type":"4"}},{"id":2867760,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Restricted Share Units","published_at":"2021-02-11T21:05:52.000Z","date":"2021-02-09","kind":"grant","acquired":true,"shares":37884,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to\ntime-based vesting and will vest on May 11, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to\ntime-based vesting and will vest on May 11, 2021."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":37884,"derivative":{"underlying":"Ordinary Shares","underlying_shares":37884},"source":{"system":"sec-edgar","filing":"0001209191-21-009633","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919121009633/doc4.xml","form_type":"4"}},{"id":2867759,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Restricted Share Units","published_at":"2021-02-11T21:05:52.000Z","date":"2021-02-09","kind":"exercise","acquired":false,"shares":16120,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"Restricted share units were granted on February 9, 2018, with 16,120 vesting on each of February 9, 2020 and February 9, 2021 and 16,121 vesting on February 9, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"Restricted share units were granted on February 9, 2018, with 16,120 vesting on each of February 9, 2020 and February 9, 2021 and 16,121 vesting on February 9, 2022."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":16121,"derivative":{"underlying":"Ordinary Shares","underlying_shares":16120},"source":{"system":"sec-edgar","filing":"0001209191-21-009633","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919121009633/doc4.xml","form_type":"4"}},{"id":2867758,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Ordinary Shares","published_at":"2021-02-11T21:05:52.000Z","date":"2021-02-09","kind":"sale","acquired":false,"shares":23639,"price":12.6945,"value":300085.2855,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"kind","element":"transactionCoding","label":"F5","text":"The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F6","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.635 to $12.785, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":100036.514,"source":{"system":"sec-edgar","filing":"0001209191-21-009633","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919121009633/doc4.xml","form_type":"4"}},{"id":2867757,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Ordinary Shares","published_at":"2021-02-11T21:05:52.000Z","date":"2021-02-09","kind":"sale","acquired":false,"shares":5857,"price":12.6945,"value":74351.6865,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"kind","element":"transactionCoding","label":"F5","text":"The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F6","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.635 to $12.785, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":123675.514,"source":{"system":"sec-edgar","filing":"0001209191-21-009633","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919121009633/doc4.xml","form_type":"4"}},{"id":2867756,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Ordinary Shares","published_at":"2021-02-11T21:05:52.000Z","date":"2021-02-09","kind":"grant","acquired":true,"shares":67852,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents ordinary shares received upon satisfaction of performance- and time-based vesting criteria of performance share units."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each performance share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources\nand Compensation Committee, the cash value of one ordinary share."}],"balance_after":129532.514,"source":{"system":"sec-edgar","filing":"0001209191-21-009633","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919121009633/doc4.xml","form_type":"4"}},{"id":2867755,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Ordinary Shares","published_at":"2021-02-11T21:05:52.000Z","date":"2021-02-09","kind":"exercise","acquired":true,"shares":16120,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."}],"balance_after":61680.514,"source":{"system":"sec-edgar","filing":"0001209191-21-009633","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919121009633/doc4.xml","form_type":"4"}},{"id":3201473,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Restricted Share Units","published_at":"2020-03-19T11:33:59.000Z","date":"2020-03-17","kind":"exercise","acquired":false,"shares":266,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Restricted share units were granted on September 9, 2016, with 265 vesting on each of March 17, 2018 and March 17, 2019 and 266 vesting on March 17, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Restricted share units were granted on September 9, 2016, with 265 vesting on each of March 17, 2018 and March 17, 2019 and 266 vesting on March 17, 2020."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":266},"source":{"system":"sec-edgar","filing":"0001209191-20-020163","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919120020163/doc4.xml","form_type":"4"}},{"id":3201472,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Restricted Share Units","published_at":"2020-03-19T11:33:59.000Z","date":"2020-03-17","kind":"exercise","acquired":false,"shares":748,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Restricted share units were granted on August 2, 2016, with 747 vesting on each of March 17, 2018 and March 17, 2019 and 748 vesting on March 17, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Restricted share units were granted on August 2, 2016, with 747 vesting on each of March 17, 2018 and March 17, 2019 and 748 vesting on March 17, 2020."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":748},"source":{"system":"sec-edgar","filing":"0001209191-20-020163","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919120020163/doc4.xml","form_type":"4"}},{"id":3201471,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Ordinary Shares","published_at":"2020-03-19T11:33:59.000Z","date":"2020-03-17","kind":"sale","acquired":false,"shares":134,"price":7.1635,"value":959.909,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"kind","element":"transactionCoding","label":"F3","text":"The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F4","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.1600 to $7.1850, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":45560.514,"source":{"system":"sec-edgar","filing":"0001209191-20-020163","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919120020163/doc4.xml","form_type":"4"}},{"id":3201470,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Ordinary Shares","published_at":"2020-03-19T11:33:59.000Z","date":"2020-03-17","kind":"sale","acquired":false,"shares":380,"price":7.1635,"value":2722.13,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"kind","element":"transactionCoding","label":"F3","text":"The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F4","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.1600 to $7.1850, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":45694.514,"source":{"system":"sec-edgar","filing":"0001209191-20-020163","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919120020163/doc4.xml","form_type":"4"}},{"id":3201469,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Ordinary Shares","published_at":"2020-03-19T11:33:59.000Z","date":"2020-03-17","kind":"exercise","acquired":true,"shares":266,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."}],"balance_after":46074.514,"source":{"system":"sec-edgar","filing":"0001209191-20-020163","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919120020163/doc4.xml","form_type":"4"}},{"id":3201468,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Ordinary Shares","published_at":"2020-03-19T11:33:59.000Z","date":"2020-03-17","kind":"exercise","acquired":true,"shares":748,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."}],"balance_after":45808.514,"source":{"system":"sec-edgar","filing":"0001209191-20-020163","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919120020163/doc4.xml","form_type":"4"}},{"id":3235425,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Restricted Share Units","published_at":"2020-03-03T12:11:29.000Z","date":"2020-02-28","kind":"grant","acquired":true,"shares":86730,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Restricted share units were granted on February 28, 2020 with 21,682 vesting on each of February 28, 2021, February 28, 2022 and February 28, 2023 and 21,684 vesting on February 28, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Restricted share units were granted on February 28, 2020 with 21,682 vesting on each of February 28, 2021, February 28, 2022 and February 28, 2023 and 21,684 vesting on February 28, 2024."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F3","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":86730,"derivative":{"underlying":"Ordinary Shares","underlying_shares":86730},"source":{"system":"sec-edgar","filing":"0001209191-20-014849","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919120014849/doc4.xml","form_type":"4"}},{"id":3268530,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Restricted Share Units","published_at":"2020-02-18T12:23:54.000Z","date":"2020-02-14","kind":"exercise","acquired":false,"shares":17850,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Restricted share units were granted on February 11, 2020 pursuant to the satisfaction of performance criteria and vested on February 14, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Restricted share units were granted on February 11, 2020 pursuant to the satisfaction of performance criteria and vested on February 14, 2020."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":17850},"source":{"system":"sec-edgar","filing":"0001209191-20-009879","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919120009879/doc4.xml","form_type":"4"}},{"id":3268529,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Restricted Share Units","published_at":"2020-02-18T12:23:54.000Z","date":"2020-02-14","kind":"exercise","acquired":false,"shares":5353,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Restricted share units were granted on February 14, 2017, with 5,353 vesting on each of February 14, 2019 and February 14, 2020 and 5,355 vesting on February 14, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Restricted share units were granted on February 14, 2017, with 5,353 vesting on each of February 14, 2019 and February 14, 2020 and 5,355 vesting on February 14, 2021."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":5355,"derivative":{"underlying":"Ordinary Shares","underlying_shares":5353},"source":{"system":"sec-edgar","filing":"0001209191-20-009879","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919120009879/doc4.xml","form_type":"4"}},{"id":3268528,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Ordinary Shares","published_at":"2020-02-18T12:23:54.000Z","date":"2020-02-14","kind":"sale","acquired":false,"shares":8825,"price":12.1422,"value":107154.915,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"kind","element":"transactionCoding","label":"F3","text":"The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F4","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.962 to $12.2800, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":45060.514,"source":{"system":"sec-edgar","filing":"0001209191-20-009879","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919120009879/doc4.xml","form_type":"4"}},{"id":3268527,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Ordinary Shares","published_at":"2020-02-18T12:23:54.000Z","date":"2020-02-14","kind":"sale","acquired":false,"shares":2647,"price":12.1422,"value":32140.4034,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"kind","element":"transactionCoding","label":"F3","text":"The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F4","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.962 to $12.2800, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":53885.514,"source":{"system":"sec-edgar","filing":"0001209191-20-009879","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919120009879/doc4.xml","form_type":"4"}},{"id":3268526,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Ordinary Shares","published_at":"2020-02-18T12:23:54.000Z","date":"2020-02-14","kind":"exercise","acquired":true,"shares":17850,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."}],"balance_after":56532.514,"source":{"system":"sec-edgar","filing":"0001209191-20-009879","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919120009879/doc4.xml","form_type":"4"}},{"id":3268525,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Ordinary Shares","published_at":"2020-02-18T12:23:54.000Z","date":"2020-02-14","kind":"exercise","acquired":true,"shares":5353,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."}],"balance_after":38682.514,"source":{"system":"sec-edgar","filing":"0001209191-20-009879","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919120009879/doc4.xml","form_type":"4"}},{"id":3275274,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Restricted Share Units","published_at":"2020-02-13T12:04:18.000Z","date":"2020-02-11","kind":"grant","acquired":true,"shares":17850,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on February 14, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on February 14, 2020."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F3","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":17850,"derivative":{"underlying":"Ordinary Shares","underlying_shares":17850},"source":{"system":"sec-edgar","filing":"0001209191-20-009049","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919120009049/doc4.xml","form_type":"4"}},{"id":3280646,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Restricted Share Units","published_at":"2020-02-11T11:57:55.000Z","date":"2020-02-09","kind":"exercise","acquired":false,"shares":16120,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Restricted share units were granted on February 9, 2018, with 16,120 vesting on each of February 9, 2020 and February 9, 2021 and 16,121 vesting on February 9, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Restricted share units were granted on February 9, 2018, with 16,120 vesting on each of February 9, 2020 and February 9, 2021 and 16,121 vesting on February 9, 2022."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":32241,"derivative":{"underlying":"Ordinary Shares","underlying_shares":16120},"source":{"system":"sec-edgar","filing":"0001209191-20-008164","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919120008164/doc4.xml","form_type":"4"}},{"id":3280645,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Ordinary Shares","published_at":"2020-02-11T11:57:55.000Z","date":"2020-02-10","kind":"sale","acquired":false,"shares":5544,"price":12.27,"value":68024.88,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"kind","element":"transactionCoding","label":"F3","text":"The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F4","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II."}],"balance_after":33329.514,"source":{"system":"sec-edgar","filing":"0001209191-20-008164","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919120008164/doc4.xml","form_type":"4"}},{"id":3280644,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Ordinary Shares","published_at":"2020-02-11T11:57:55.000Z","date":"2020-02-09","kind":"exercise","acquired":true,"shares":16120,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."}],"balance_after":38873.514,"source":{"system":"sec-edgar","filing":"0001209191-20-008164","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919120008164/doc4.xml","form_type":"4"}},{"id":3328140,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Restricted Share Units","published_at":"2020-01-02T11:08:55.000Z","date":"2019-12-31","kind":"exercise","acquired":false,"shares":4640,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Restricted share units were granted on July 1, 2014, with 4,640 vesting on each of December 31, 2018 and December 31, 2019."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Restricted share units were granted on July 1, 2014, with 4,640 vesting on each of December 31, 2018 and December 31, 2019."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":4640},"source":{"system":"sec-edgar","filing":"0001209191-20-000005","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919120000005/doc4.xml","form_type":"4"}},{"id":3328139,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Ordinary Shares","published_at":"2020-01-02T11:08:55.000Z","date":"2019-12-31","kind":"sale","acquired":false,"shares":2459,"price":9.9212,"value":24396.2308,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"kind","element":"transactionCoding","label":"F3","text":"The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F4","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.92 to $9.9238, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":22753.514,"source":{"system":"sec-edgar","filing":"0001209191-20-000005","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919120000005/doc4.xml","form_type":"4"}},{"id":3328138,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Ordinary Shares","published_at":"2020-01-02T11:08:55.000Z","date":"2019-12-31","kind":"exercise","acquired":true,"shares":4640,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."}],"balance_after":25212.514,"source":{"system":"sec-edgar","filing":"0001209191-20-000005","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919120000005/doc4.xml","form_type":"4"}},{"id":3355173,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Restricted Share Units","published_at":"2019-12-03T11:32:03.000Z","date":"2019-11-30","kind":"exercise","acquired":false,"shares":8133,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Restricted share units were granted on November 30, 2016, with 2,711 vesting on November 30, 2018 and 8,133 vesting on November 30, 2019."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Restricted share units were granted on November 30, 2016, with 2,711 vesting on November 30, 2018 and 8,133 vesting on November 30, 2019."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":8133},"source":{"system":"sec-edgar","filing":"0001209191-19-058620","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919119058620/doc4.xml","form_type":"4"}},{"id":3355172,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Ordinary Shares","published_at":"2019-12-03T11:32:03.000Z","date":"2019-12-02","kind":"sale","acquired":false,"shares":4310,"price":10.4906,"value":45214.486,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"kind","element":"transactionCoding","label":"F3","text":"The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F4","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.490 to $10.495, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":20572.514,"source":{"system":"sec-edgar","filing":"0001209191-19-058620","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919119058620/doc4.xml","form_type":"4"}},{"id":3355171,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Ordinary Shares","published_at":"2019-12-03T11:32:03.000Z","date":"2019-11-30","kind":"exercise","acquired":true,"shares":8133,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."}],"balance_after":24882.514,"source":{"system":"sec-edgar","filing":"0001209191-19-058620","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919119058620/doc4.xml","form_type":"4"}},{"id":3589259,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Restricted Share Units","published_at":"2019-03-19T12:04:34.000Z","date":"2019-03-17","kind":"exercise","acquired":false,"shares":265,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Restricted share units were granted on September 9, 2016, with 265 vesting on each of March 17, 2018 and March 17, 2019 and 266 vesting on March 17, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Restricted share units were granted on September 9, 2016, with 265 vesting on each of March 17, 2018 and March 17, 2019 and 266 vesting on March 17, 2020."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":266,"derivative":{"underlying":"Ordinary Shares","underlying_shares":265},"source":{"system":"sec-edgar","filing":"0001209191-19-020157","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919119020157/doc4.xml","form_type":"4"}},{"id":3589258,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Restricted Share Units","published_at":"2019-03-19T12:04:34.000Z","date":"2019-03-17","kind":"exercise","acquired":false,"shares":747,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Restricted share units were granted on August 2, 2016, with 747 vesting on each of March 17, 2018 and March 17, 2019 and 748 vesting on March 17, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Restricted share units were granted on August 2, 2016, with 747 vesting on each of March 17, 2018 and March 17, 2019 and 748 vesting on March 17, 2020."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":748,"derivative":{"underlying":"Ordinary Shares","underlying_shares":747},"source":{"system":"sec-edgar","filing":"0001209191-19-020157","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919119020157/doc4.xml","form_type":"4"}},{"id":3589257,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Ordinary Shares","published_at":"2019-03-19T12:04:34.000Z","date":"2019-03-18","kind":"sale","acquired":false,"shares":93,"price":16.6251,"value":1546.1343,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"kind","element":"transactionCoding","label":"F3","text":"The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F4","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.5800 to $16.6800, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":16749.514,"source":{"system":"sec-edgar","filing":"0001209191-19-020157","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919119020157/doc4.xml","form_type":"4"}},{"id":3589256,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Ordinary Shares","published_at":"2019-03-19T12:04:34.000Z","date":"2019-03-18","kind":"sale","acquired":false,"shares":263,"price":16.6251,"value":4372.4013,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"kind","element":"transactionCoding","label":"F3","text":"The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F4","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.5800 to $16.6800, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":16842.514,"source":{"system":"sec-edgar","filing":"0001209191-19-020157","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919119020157/doc4.xml","form_type":"4"}},{"id":3589255,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Ordinary Shares","published_at":"2019-03-19T12:04:34.000Z","date":"2019-03-17","kind":"exercise","acquired":true,"shares":265,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."}],"balance_after":17105.514,"source":{"system":"sec-edgar","filing":"0001209191-19-020157","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919119020157/doc4.xml","form_type":"4"}},{"id":3589254,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Ordinary Shares","published_at":"2019-03-19T12:04:34.000Z","date":"2019-03-17","kind":"exercise","acquired":true,"shares":747,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."}],"balance_after":16840.514,"source":{"system":"sec-edgar","filing":"0001209191-19-020157","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919119020157/doc4.xml","form_type":"4"}},{"id":3609902,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Restricted Share Units","published_at":"2019-03-06T12:14:01.000Z","date":"2019-03-04","kind":"grant","acquired":true,"shares":56716,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Restricted share units were granted on March 4, 2019, with 18,905 vesting on each of March 4, 2021 and March 4, 2022 and 18,906 vesting on March 4, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Restricted share units were granted on March 4, 2019, with 18,905 vesting on each of March 4, 2021 and March 4, 2022 and 18,906 vesting on March 4, 2023."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F3","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":56716,"derivative":{"underlying":"Ordinary Shares","underlying_shares":56716},"source":{"system":"sec-edgar","filing":"0001209191-19-017230","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919119017230/doc4.xml","form_type":"4"}},{"id":3616181,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Restricted Share Units","published_at":"2019-03-05T12:16:54.000Z","date":"2019-03-04","kind":"exercise","acquired":false,"shares":1165,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Restricted share units were granted on March 4, 2015, with 1,165 vesting on each of March 4, 2018 and March 4, 2019."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Restricted share units were granted on March 4, 2015, with 1,165 vesting on each of March 4, 2018 and March 4, 2019."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":1165},"source":{"system":"sec-edgar","filing":"0001209191-19-016085","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919119016085/doc4.xml","form_type":"4"}},{"id":3616180,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Ordinary Shares","published_at":"2019-03-05T12:16:54.000Z","date":"2019-03-04","kind":"sale","acquired":false,"shares":409,"price":16.8833,"value":6905.2697,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"kind","element":"transactionCoding","label":"F3","text":"The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F4","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.755 to $17.130, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":16093.514,"source":{"system":"sec-edgar","filing":"0001209191-19-016085","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919119016085/doc4.xml","form_type":"4"}},{"id":3616179,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Ordinary Shares","published_at":"2019-03-05T12:16:54.000Z","date":"2019-03-04","kind":"exercise","acquired":true,"shares":1165,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."}],"balance_after":16502.514,"source":{"system":"sec-edgar","filing":"0001209191-19-016085","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919119016085/doc4.xml","form_type":"4"}},{"id":3651694,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Restricted Share Units","published_at":"2019-02-19T12:11:24.000Z","date":"2019-02-14","kind":"exercise","acquired":false,"shares":5353,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Restricted share units were granted on February 14, 2017, with 5,353 vesting on each of February 14, 2019 and February 14, 2020 and 5,355 vesting on February 14, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Restricted share units were granted on February 14, 2017, with 5,353 vesting on each of February 14, 2019 and February 14, 2020 and 5,355 vesting on February 14, 2021."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":10708,"derivative":{"underlying":"Ordinary Shares","underlying_shares":5353},"source":{"system":"sec-edgar","filing":"0001209191-19-010837","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919119010837/doc4.xml","form_type":"4"}},{"id":3651693,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Ordinary Shares","published_at":"2019-02-19T12:11:24.000Z","date":"2019-02-14","kind":"sale","acquired":false,"shares":1841,"price":17.669,"value":32528.629,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"kind","element":"transactionCoding","label":"F3","text":"The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F4","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.66 to $17.675, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":15337.514,"source":{"system":"sec-edgar","filing":"0001209191-19-010837","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919119010837/doc4.xml","form_type":"4"}},{"id":3651692,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Ordinary Shares","published_at":"2019-02-19T12:11:24.000Z","date":"2019-02-14","kind":"exercise","acquired":true,"shares":5353,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."}],"balance_after":17178.514,"source":{"system":"sec-edgar","filing":"0001209191-19-010837","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919119010837/doc4.xml","form_type":"4"}},{"id":3711269,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Restricted Share Units","published_at":"2019-01-03T12:24:16.000Z","date":"2018-12-31","kind":"exercise","acquired":false,"shares":4640,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Restricted share units were granted on July 1, 2014, with 4,640 vesting on each of December 31, 2018 and December 31, 2019."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Restricted share units were granted on July 1, 2014, with 4,640 vesting on each of December 31, 2018 and December 31, 2019."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":4640,"derivative":{"underlying":"Ordinary Shares","underlying_shares":4640},"source":{"system":"sec-edgar","filing":"0001209191-19-000609","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919119000609/doc4.xml","form_type":"4"}},{"id":3711268,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Ordinary Shares","published_at":"2019-01-03T12:24:16.000Z","date":"2019-01-02","kind":"sale","acquired":false,"shares":1643,"price":15.7025,"value":25799.2075,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"kind","element":"transactionCoding","label":"F3","text":"The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F4","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.7 to $15.705, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":11825.514,"source":{"system":"sec-edgar","filing":"0001209191-19-000609","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919119000609/doc4.xml","form_type":"4"}},{"id":3711267,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Ordinary Shares","published_at":"2019-01-03T12:24:16.000Z","date":"2018-12-31","kind":"exercise","acquired":true,"shares":4640,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."}],"balance_after":13468.514,"source":{"system":"sec-edgar","filing":"0001209191-19-000609","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919119000609/doc4.xml","form_type":"4"}},{"id":3745024,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Restricted Share Units","published_at":"2018-12-04T13:09:50.000Z","date":"2018-11-30","kind":"exercise","acquired":false,"shares":2711,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Restricted share units were granted on November 30, 2016, with 2,711 vesting on November 30, 2018 and 8,133 vesting on November 30, 2019."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Restricted share units were granted on November 30, 2016, with 2,711 vesting on November 30, 2018 and 8,133 vesting on November 30, 2019."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":8133,"derivative":{"underlying":"Ordinary Shares","underlying_shares":2711},"source":{"system":"sec-edgar","filing":"0001209191-18-060707","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919118060707/doc4.xml","form_type":"4"}},{"id":3745023,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Ordinary Shares","published_at":"2018-12-04T13:09:50.000Z","date":"2018-11-30","kind":"sale","acquired":false,"shares":933,"price":21.7621,"value":20304.0393,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.7600 to $21.7638, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":8828.514,"source":{"system":"sec-edgar","filing":"0001209191-18-060707","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919118060707/doc4.xml","form_type":"4"}},{"id":3745022,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Ordinary Shares","published_at":"2018-12-04T13:09:50.000Z","date":"2018-11-30","kind":"exercise","acquired":true,"shares":2711,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."}],"balance_after":9761.514,"source":{"system":"sec-edgar","filing":"0001209191-18-060707","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919118060707/doc4.xml","form_type":"4"}},{"id":3988461,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Restricted Share Units","published_at":"2018-03-20T20:07:45.000Z","date":"2018-03-17","kind":"exercise","acquired":false,"shares":265,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Restricted share units were granted on September 9, 2016, with 265 vesting on each of March 17, 2018 and March 17, 2019 and 266 vesting on March 17, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Restricted share units were granted on September 9, 2016, with 265 vesting on each of March 17, 2018 and March 17, 2019 and 266 vesting on March 17, 2020."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":531,"derivative":{"underlying":"Ordinary Shares","underlying_shares":265},"source":{"system":"sec-edgar","filing":"0001209191-18-020859","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919118020859/doc4.xml","form_type":"4"}},{"id":3988460,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Restricted Share Units","published_at":"2018-03-20T20:07:45.000Z","date":"2018-03-17","kind":"exercise","acquired":false,"shares":747,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Restricted share units were granted on August 2, 2016, with 747 vesting on each of March 17, 2018 and March 17, 2019 and 748 vesting on March 17, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Restricted share units were granted on August 2, 2016, with 747 vesting on each of March 17, 2018 and March 17, 2019 and 748 vesting on March 17, 2020."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":1495,"derivative":{"underlying":"Ordinary Shares","underlying_shares":747},"source":{"system":"sec-edgar","filing":"0001209191-18-020859","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919118020859/doc4.xml","form_type":"4"}},{"id":3988459,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Ordinary Shares","published_at":"2018-03-20T20:07:45.000Z","date":"2018-03-19","kind":"sale","acquired":false,"shares":91,"price":17.878,"value":1626.898,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.83 to $17.925, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":7050.514,"source":{"system":"sec-edgar","filing":"0001209191-18-020859","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919118020859/doc4.xml","form_type":"4"}},{"id":3988458,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Ordinary Shares","published_at":"2018-03-20T20:07:45.000Z","date":"2018-03-19","kind":"sale","acquired":false,"shares":257,"price":17.878,"value":4594.646,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.83 to $17.925, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":7141.514,"source":{"system":"sec-edgar","filing":"0001209191-18-020859","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919118020859/doc4.xml","form_type":"4"}},{"id":3988457,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Ordinary Shares","published_at":"2018-03-20T20:07:45.000Z","date":"2018-03-17","kind":"exercise","acquired":true,"shares":265,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."}],"balance_after":7398.514,"source":{"system":"sec-edgar","filing":"0001209191-18-020859","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919118020859/doc4.xml","form_type":"4"}},{"id":3988456,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Ordinary Shares","published_at":"2018-03-20T20:07:45.000Z","date":"2018-03-17","kind":"exercise","acquired":true,"shares":747,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."}],"balance_after":7133.514,"source":{"system":"sec-edgar","filing":"0001209191-18-020859","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919118020859/doc4.xml","form_type":"4"}},{"id":4012708,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Restricted Share Units","published_at":"2018-03-06T21:12:39.000Z","date":"2018-03-05","kind":"exercise","acquired":false,"shares":3432,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Restricted share units were granted on May 8, 2014 and vest on March 5, 2018."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Restricted share units were granted on May 8, 2014 and vest on March 5, 2018."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":3432},"source":{"system":"sec-edgar","filing":"0001209191-18-017207","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919118017207/doc4.xml","form_type":"4"}},{"id":4012707,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Restricted Share Units","published_at":"2018-03-06T21:12:39.000Z","date":"2018-03-04","kind":"exercise","acquired":false,"shares":1165,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Restricted share units were granted on March 4, 2015, with 1,165 vesting on each of March 4, 2018 and March 4, 2019."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Restricted share units were granted on March 4, 2015, with 1,165 vesting on each of March 4, 2018 and March 4, 2019."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":1165,"derivative":{"underlying":"Ordinary Shares","underlying_shares":1165},"source":{"system":"sec-edgar","filing":"0001209191-18-017207","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919118017207/doc4.xml","form_type":"4"}},{"id":4012706,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Ordinary Shares","published_at":"2018-03-06T21:12:39.000Z","date":"2018-03-05","kind":"tax_withholding","acquired":false,"shares":1155,"price":19.38,"value":22383.9,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":6386.514,"source":{"system":"sec-edgar","filing":"0001209191-18-017207","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919118017207/doc4.xml","form_type":"4"}},{"id":4012705,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Ordinary Shares","published_at":"2018-03-06T21:12:39.000Z","date":"2018-03-05","kind":"tax_withholding","acquired":false,"shares":400,"price":19.38,"value":7752.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":7541.514,"source":{"system":"sec-edgar","filing":"0001209191-18-017207","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919118017207/doc4.xml","form_type":"4"}},{"id":4012704,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Ordinary Shares","published_at":"2018-03-06T21:12:39.000Z","date":"2018-03-05","kind":"exercise","acquired":true,"shares":3432,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."}],"balance_after":7941.514,"source":{"system":"sec-edgar","filing":"0001209191-18-017207","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919118017207/doc4.xml","form_type":"4"}},{"id":4012703,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Ordinary Shares","published_at":"2018-03-06T21:12:39.000Z","date":"2018-03-04","kind":"exercise","acquired":true,"shares":1165,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."}],"balance_after":4509.514,"source":{"system":"sec-edgar","filing":"0001209191-18-017207","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919118017207/doc4.xml","form_type":"4"}},{"id":4067051,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Restricted Share Units","published_at":"2018-02-12T21:21:25.000Z","date":"2018-02-09","kind":"grant","acquired":true,"shares":48361,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Restricted share units were granted on February 9, 2018, with 16,120 vesting on each of February 9, 2020 and February 9, 2021 and 16,121 vesting on February 9, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Restricted share units were granted on February 9, 2018, with 16,120 vesting on each of February 9, 2020 and February 9, 2021 and 16,121 vesting on February 9, 2022."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":48361,"derivative":{"underlying":"Ordinary Shares","underlying_shares":48361},"source":{"system":"sec-edgar","filing":"0001209191-18-009186","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919118009186/doc4.xml","form_type":"4"}},{"id":4067050,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":127160,"kind":"person","name":"Fridriksdottir Hafrun","position":1,"cik":"0001561458","reported_name":"Fridriksdottir Hafrun","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, Global R&D"}}],"security":"Stock Options (right to buy)","published_at":"2018-02-12T21:21:25.000Z","date":"2018-02-09","kind":"grant","acquired":true,"shares":123288,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Stock options were granted on February 9, 2018, with 41,096 vesting on each of February 9, 2020, February 9, 2021 and February 9, 2022."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":123288,"derivative":{"exercise_price":18.61,"expiration_date":"2028-02-08","underlying":"Ordinary Shares","underlying_shares":123288},"source":{"system":"sec-edgar","filing":"0001209191-18-009186","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919118009186/doc4.xml","form_type":"4"}}]}